NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin | BMJ Supportive & Palliative Care

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

PDF +
Supplementary
Material

Original research

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Yeo W, Lau TK, Kwok CC, et al

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin

BMJ Supportive & Palliative Care 2022;12:e264-e270.